ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Companyâs corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as President and Chief Executive Officer for the past 24 years.
Related Questions
What is the market's perception of the leadership transition after a 24âyear tenure by Scott Koenig?
Will the new CEO's track record in generating $1.6âŻB of nonâdilutive capital translate into accelerated funding for upcoming clinical programs?
How might this management change impact the valuation of MacroGenics' existing pipeline and partnership agreements?
Are there any anticipated changes in corporate strategy or partnership focus under Eric Risser's leadership?
Could the leadership change trigger a reâpricing of the stock relative to peers in the antibodyâtherapeutics space?
Will the board composition shift with the addition of Risser, and how could that influence governance risk assessments?
How does the market historically react to longâstanding CEO transitions in similar biotech companies?
How will the appointment of Eric Risser as CEO affect MacroGenics' short-term stock momentum?
What is the expected effect on analyst coverage and consensus estimates following the CEO appointment?
Is there any insider trading activity or option activity surrounding the announcement that could signal market sentiment?